tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
De-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360
PremiumRatingsDe-Risked Clinical Profile and Growing Commercial Infrastructure Support Buy Rating on COMPASS Pathways’ COMP360
1M ago
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
Premium
The Fly
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
1M ago
Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside
Premium
Ratings
Advancing COMP360 From Binary Clinical Risk to Scaled Commercial Opportunity: Buy Rating Reaffirmed on De-Risked TRD Launch and PTSD Upside
1M ago
Psychedelic: Atai Beckley granted U.S. patent for EMP-01
PremiumThe FlyPsychedelic: Atai Beckley granted U.S. patent for EMP-01
2M ago
Compass Pathways upgraded to Outperform at Oppenheimer on COMP360 potential
Premium
The Fly
Compass Pathways upgraded to Outperform at Oppenheimer on COMP360 potential
2M ago
Compass Pathways upgraded to Outperform from Perform at Oppenheimer
Premium
The Fly
Compass Pathways upgraded to Outperform from Perform at Oppenheimer
2M ago
Accelerated Phase 3 Timeline and Strong Financials Boost COMPASS Pathways’ Prospects
PremiumRatingsAccelerated Phase 3 Timeline and Strong Financials Boost COMPASS Pathways’ Prospects
3M ago
Is CMPS a Buy, Before Earnings?
Premium
Pre-Earnings
Is CMPS a Buy, Before Earnings?
3M ago
Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration
Premium
The Fly
Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100